Search Videos and More
News
Antibody-Drug Conjugate Shows Impressive Activity in Patients with Non-Small Cell Lung Cancer with Mutation in HER2 Gene
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
News
New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs
Multiple acquired resistance mechanisms discovered for cancers with KRASG12C mutation after treatment with KRASG12C inhibitors.
News
Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy
Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune checkpoint inhibitors.